Abstract
In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis of novel N-(benzoylphenyl)-5-substituted-1
H
-indole-2-carboxamides (compounds
8
-
12
,
15
,
16
,
18
) and investigating their antihyperlipidemic activity using Triton WR-1339-induced hyperlipidemic rats as an experimental model. Hyperlipidemia was developed by intraperitoneal injection of Triton WR-1339 (250 mg/kg body weight). The tested animals were divided into normal control (NCG), hyperlipidemic (HG), compound
8
,
9
,
15
,
16
,
18
- and bezafibrate treated groups. At a dose of 15 mg/kg body weight, compounds
9
,
16
,
18
and bezafibrate (100 mg/kg) significantly (
p
< 0.0001) reduced elevated plasma triglycerides levels after 12 h compared to the hyperlipidemic control group. However, only the group treated with compounds
9
,
16
and
18
showed an obviously significant (
p
< 0.001) reduction in plasma total cholesterol levels after 12 h compared to the hyperlipidemic control group. Moreover, high density lipoprotein-cholesterol levels were significantly (
p
< 0.0001) increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for compounds
8
and
15
which revealed inactive. It is therefore reasonable to assume that compounds
9
,
16
and
18
may have potential in the treatment of hyperlipidemia.